Amgen "outperform," target price reduced

27.01.09 - Credit Suisse

NEW YORK, January 27 (newratings.com) - Analysts at Credit Suisse reiterate their "outperform" rating on Amgen (AMGN). The target price has been reduced from $72 to $68.